Études transversales : Questions médicales fréquentes
Nom anglais: Cross-Sectional Studies
Descriptor UI:D003430
Tree Number:N06.850.520.450.500.875
Termes MeSH sélectionnés :
Cognitive Dysfunction
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Études transversales : Questions médicales les plus fréquentes",
"headline": "Études transversales : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Études transversales : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Études transversales"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Études épidémiologiques",
"url": "https://questionsmedicales.fr/mesh/D016021",
"about": {
"@type": "MedicalCondition",
"name": "Études épidémiologiques",
"code": {
"@type": "MedicalCode",
"code": "D016021",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N06.850.520.450.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Études transversales",
"alternateName": "Cross-Sectional Studies",
"code": {
"@type": "MedicalCode",
"code": "D003430",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Andreea Teodora Constantin",
"url": "https://questionsmedicales.fr/author/Andreea%20Teodora%20Constantin",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Medicine, University of Medicine and Pharmacy \"Carol Davila\", 020021 Bucharest, Romania."
}
},
{
"@type": "Person",
"name": "Ioana Rosca",
"url": "https://questionsmedicales.fr/author/Ioana%20Rosca",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Midwifery and Nursery, University of Medicine and Pharmacy \"Carol Davila\", 020021 Bucharest, Romania."
}
},
{
"@type": "Person",
"name": "Mandana Hoseini",
"url": "https://questionsmedicales.fr/author/Mandana%20Hoseini",
"affiliation": {
"@type": "Organization",
"name": "PhD graduate, Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Fateme Jalousian",
"url": "https://questionsmedicales.fr/author/Fateme%20Jalousian",
"affiliation": {
"@type": "Organization",
"name": "Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Seyed Hosein Hoseini",
"url": "https://questionsmedicales.fr/author/Seyed%20Hosein%20Hoseini",
"affiliation": {
"@type": "Organization",
"name": "Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.",
"datePublished": "2022-10-17",
"url": "https://questionsmedicales.fr/article/36251860",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/13506129.2022.2131384"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.",
"datePublished": "2024-09-13",
"url": "https://questionsmedicales.fr/article/39346594",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2024.1385089"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reward network dysfunction is associated with cognitive impairment after stroke.",
"datePublished": "2023-05-31",
"url": "https://questionsmedicales.fr/article/37307650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nicl.2023.103446"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors of cognitive dysfunction one-year post COVID-19.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36603126",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/neu0000876"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36729842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/RHU.0000000000001888"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Environnement et santé publique",
"item": "https://questionsmedicales.fr/mesh/D004778"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé publique",
"item": "https://questionsmedicales.fr/mesh/D011634"
},
{
"@type": "ListItem",
"position": 4,
"name": "Méthodes épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D004812"
},
{
"@type": "ListItem",
"position": 5,
"name": "Caractéristiques des études épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D016020"
},
{
"@type": "ListItem",
"position": 6,
"name": "Études épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D016021"
},
{
"@type": "ListItem",
"position": 7,
"name": "Études transversales",
"item": "https://questionsmedicales.fr/mesh/D003430"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Études transversales - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Études transversales",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Études transversales",
"description": "Comment les études transversales aident-elles au diagnostic ?\nPeut-on établir un diagnostic définitif avec une étude transversale ?\nQuel type de données recueille une étude transversale ?\nLes études transversales peuvent-elles identifier des biomarqueurs ?\nQuel est l'avantage principal des études transversales pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D003430?mesh_terms=Cognitive+Dysfunction&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Études transversales",
"description": "Les études transversales identifient-elles des symptômes ?\nPeut-on relier des symptômes à des facteurs de risque via ces études ?\nComment les symptômes sont-ils mesurés dans ces études ?\nLes études transversales peuvent-elles révéler des symptômes rares ?\nLes symptômes peuvent-ils varier selon les groupes d'âge dans ces études ?",
"url": "https://questionsmedicales.fr/mesh/D003430?mesh_terms=Cognitive+Dysfunction&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Études transversales",
"description": "Les études transversales aident-elles à identifier des stratégies de prévention ?\nPeut-on évaluer l'impact des programmes de prévention avec ces études ?\nComment les comportements préventifs sont-ils mesurés ?\nLes études transversales peuvent-elles identifier des populations à risque ?\nLes résultats des études transversales influencent-ils les politiques de santé publique ?",
"url": "https://questionsmedicales.fr/mesh/D003430?mesh_terms=Cognitive+Dysfunction&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Études transversales",
"description": "Les études transversales évaluent-elles l'efficacité des traitements ?\nPeut-on observer des tendances de traitement dans ces études ?\nLes études transversales peuvent-elles influencer les pratiques de traitement ?\nComment les traitements sont-ils documentés dans ces études ?\nLes études transversales peuvent-elles révéler des inégalités dans l'accès aux traitements ?",
"url": "https://questionsmedicales.fr/mesh/D003430?mesh_terms=Cognitive+Dysfunction&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Études transversales",
"description": "Les études transversales peuvent-elles identifier des complications associées ?\nComment les complications sont-elles documentées dans ces études ?\nPeut-on évaluer la gravité des complications avec ces études ?\nLes études transversales peuvent-elles révéler des complications rares ?\nLes complications peuvent-elles varier selon les groupes démographiques ?",
"url": "https://questionsmedicales.fr/mesh/D003430?mesh_terms=Cognitive+Dysfunction&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Études transversales",
"description": "Les études transversales identifient-elles des facteurs de risque ?\nPeut-on établir une causalité avec des études transversales ?\nComment les facteurs de risque sont-ils mesurés ?\nLes études transversales peuvent-elles révéler des facteurs de risque émergents ?\nLes facteurs de risque varient-ils selon les populations étudiées ?",
"url": "https://questionsmedicales.fr/mesh/D003430?mesh_terms=Cognitive+Dysfunction&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment les études transversales aident-elles au diagnostic ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer la prévalence des maladies et d'identifier des associations."
}
},
{
"@type": "Question",
"name": "Peut-on établir un diagnostic définitif avec une étude transversale ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles fournissent des données descriptives mais ne permettent pas de causalité."
}
},
{
"@type": "Question",
"name": "Quel type de données recueille une étude transversale ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des données sur la santé, les comportements et les caractéristiques démographiques."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles identifier des biomarqueurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent suggérer des biomarqueurs associés à des conditions, mais pas prouver leur causalité."
}
},
{
"@type": "Question",
"name": "Quel est l'avantage principal des études transversales pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent une évaluation rapide et peu coûteuse de la santé d'une population."
}
},
{
"@type": "Question",
"name": "Les études transversales identifient-elles des symptômes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent décrire la prévalence des symptômes dans une population donnée."
}
},
{
"@type": "Question",
"name": "Peut-on relier des symptômes à des facteurs de risque via ces études ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent montrer des associations, mais ne prouvent pas de relations causales."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils mesurés dans ces études ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des questionnaires, des entretiens ou des examens cliniques standardisés."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles révéler des symptômes rares ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont moins efficaces pour les symptômes rares en raison de la taille de l'échantillon."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier selon les groupes d'âge dans ces études ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les études peuvent montrer des variations de symptômes selon les tranches d'âge."
}
},
{
"@type": "Question",
"name": "Les études transversales aident-elles à identifier des stratégies de prévention ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent suggérer des facteurs de risque à cibler pour des interventions préventives."
}
},
{
"@type": "Question",
"name": "Peut-on évaluer l'impact des programmes de prévention avec ces études ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne mesurent que la prévalence avant l'implémentation des programmes."
}
},
{
"@type": "Question",
"name": "Comment les comportements préventifs sont-ils mesurés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des questionnaires sur les habitudes de vie et les comportements de santé."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles identifier des populations à risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent révéler des groupes à risque élevé pour cibler les efforts de prévention."
}
},
{
"@type": "Question",
"name": "Les résultats des études transversales influencent-ils les politiques de santé publique ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles fournissent des données essentielles pour orienter les politiques de santé publique."
}
},
{
"@type": "Question",
"name": "Les études transversales évaluent-elles l'efficacité des traitements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne mesurent que la prévalence des traitements, pas leur efficacité."
}
},
{
"@type": "Question",
"name": "Peut-on observer des tendances de traitement dans ces études ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent montrer des tendances dans l'utilisation des traitements au sein d'une population."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles influencer les pratiques de traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent fournir des données qui orientent les décisions cliniques et les politiques de santé."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils documentés dans ces études ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des enquêtes sur les antécédents médicaux et les traitements en cours des participants."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles révéler des inégalités dans l'accès aux traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent mettre en lumière des disparités dans l'accès aux soins et aux traitements."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles identifier des complications associées ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent montrer des associations entre maladies et complications, mais pas de causalité."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles documentées dans ces études ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des rapports de cas, des questionnaires et des examens cliniques des participants."
}
},
{
"@type": "Question",
"name": "Peut-on évaluer la gravité des complications avec ces études ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles ne mesurent que la prévalence, pas la gravité ou l'évolution des complications."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles révéler des complications rares ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont moins efficaces pour identifier des complications rares en raison de la taille de l'échantillon."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles varier selon les groupes démographiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les études peuvent montrer des variations de complications selon l'âge, le sexe, etc."
}
},
{
"@type": "Question",
"name": "Les études transversales identifient-elles des facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent révéler des associations entre facteurs de risque et maladies."
}
},
{
"@type": "Question",
"name": "Peut-on établir une causalité avec des études transversales ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles montrent des associations mais ne peuvent pas prouver la causalité."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils mesurés ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des questionnaires, des entretiens et des données cliniques des participants."
}
},
{
"@type": "Question",
"name": "Les études transversales peuvent-elles révéler des facteurs de risque émergents ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent identifier de nouveaux facteurs de risque à étudier plus en profondeur."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque varient-ils selon les populations étudiées ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les études peuvent montrer des variations de facteurs de risque selon les groupes."
}
}
]
}
]
}
Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy....
The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT)....
A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive comp...
Cognitive dysfunction was identified in 35 patients (13%)-14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patient...
Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients t...
The impact of cardiovascular diseases on cognition raises important research questions. The study aimed to investigate the relationship between demographic data, cardiovascular diseases, kidney diseas...
A cross-sectional study of patients with cardiovascular diseases was performed. The Montreal Cognitive Assessment (MoCA) was applied for cognitive evaluation. Based on MoCA three groups were defined: ...
Of 628 patients, 55.2% had mild CD, and the mean age was 67.95 (SD 9.53) years. Cα and Mω were 0.7, indicating good internal consistency. We found a moderate positive correlation between depression an...
Mild CD was the most common in patients with cardiovascular diseases. Older age, lower education, being a non-smoker, and renal dysfunction were risk factors for both mild and advanced CD. Female gend...
Stroke survivors not only suffer from severe motor, speech and neurocognitive deficits, but in many cases also from a "lack of pleasure" and a reduced motivational level. Especially apathy and anhedon...
(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitiv...
One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Vis...
Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acut...
A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infe...
During the last years, a growing number of studies have investigated the link between cognitive dysfunction and rheumatoid arthritis (RA), highlighting the potential pathogenic role of several clinica...
We performed a systematic review using PRISMA (Preferred Reported Items for Systematic Reviews and Meta-analysis) protocol. A systematic search was conducted in the PubMed/MEDLINE, EMBASE, LILACS, Sco...
Five original studies were included, which provided data from 428 participants. Among plasma proteins, SHH was increased and TTR was reduced in patients with mild cognitive impairment; anti-myelin bas...
Despite the relative scarcity of studies on this subject and the heterogeneity of results, we identified possible biomarkers for cognitive deficits in the RA population. Further longitudinal studies a...
Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) with a well-documented role in the innate and adaptive immune responses. Interestingly, TLR activation has also been linked to sever...
The origin of pre-existing cognitive impairment in stroke patients remains controversial, with a vascular or a degenerative hypothesis....
To determine whether endothelial dysfunction is associated with pre-existing cognitive problems, lesion load and biological anomalies in stroke patients....
Patients originated from the prospective STROKDEM study. The baseline cognitive state, assessed using the IQ-CODE, and risk factors for stroke were recorded at inclusion. Patients with an IQ-CODE scor...
A total of 86 patients were included (52 males; mean age 63.5 ± 11.5 years). Patients with abnormal RHI have hypertension or antihypertensive treatment more often. The baseline IQ-CODE was abnormal in...
A vascular mechanism may be responsible for cognitive problems pre-existing stroke. The measurement of endothelial dysfunction after stroke could become an important element of follow-up, providing an...
There is increasing recognition of the prevalence and impact of cognitive dysfunction (CD) in heart failure (HF) patients. This contemporary review appraises the evidence for epidemiological associati...
CD disproportionately affects heart failure patients, even accounting for known comorbid risk factors, and this may extend to subclinical left ventricular dysfunction. Neuroimaging studies now provide...
Cognitive dysfunction is increasingly recognized as a complication and comorbidity of diabetes, supported by evidence of abnormal brain structure and function. Although few mechanistic metabolic studi...
There is limited data on cognition in patients undergoing peritoneal dialysis (PD). We assessed prevalence and associated risk factors of neurocognitive impairment (NCI) in PD patients....
A cross-sectional cohort study of 149 PD patients at a single centre between 2016 and 2020 who underwent neurocognitive screening at defined intervals by Addenbrooke's Cognitive Examination - Revised ...
Patients on PD performed poorly in ACE-R screening compared to population norms, with discrepancy in all cognitive domains. In patients without CVD, attention and language domains were comparable to n...
Patients on PD have higher prevalence of NCI than the general population, primarily with impairments in memory, fluency and visuospatial reasoning. CVD confers poorer performance in attention and lang...